Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback